Gene therapy: Is IL2RG oncogenic in T-cell development?: X-SCID transgene leukaemogenicity (reply)

Nature

Volumn 443, Issue 7109, 2006, Pages

  Woods, Niels Bjarne ^a   Bottero, Virginie ^a   Schmidt, Manfred ^b   Von Kalle, Christof ^b   Verma, Inder M ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR RECEPTOR; INTERLEUKIN 2 RECEPTOR GAMMA; JANUS KINASE 3; LENTIVIRUS VECTOR; RETROVIRUS VECTOR;

CARCINOGENESIS; COMBINED IMMUNODEFICIENCY; GENE; GENE ACTIVATION; GENE INSERTION; GENE LOCUS; GENE OVEREXPRESSION; HUMAN; IL2RG GENE; LMO2 GENE; LONG TERMINAL REPEAT; LYMPHOCYTE PROLIFERATION; MUTAGENESIS; NONHUMAN; NOTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THYMUS LYMPHOMA; TRANSGENE; X LINKED SEVERE COMBINED IMMUNE DEFICIENCY;

EID: 33748933210     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature05220     Document Type: Note

References (9)

1. Woods, N.-B., Bottero, V., Schmidt, M., von Kalle, C. & Verma, I. M. Nature 440, 1123 (2006).
2. Pike-Overzet, K. et al. Nature 443, doi:10.1038/ nature05218 (2006).
3. Thrasher, A. J. et al. Nature 443, doi:10.1038/nature05219 (2006).
4. Montini, E. et al. Nature Biotechnol. 24, 687-696 (2006).
5. Soudais, C. et al. Blood 95, 3071-3077 (2000).
6. Lo, M. et al. Blood 94, 3027-3036 (1999).
7. Otsu, M. et al. Mol. Ther. 1, 145-153 (2000).
8. Otsu, M., Sugamura, K. & Candotti, F. Blood 97, 1618-1624 (2001).
9. Aviles Mendoza, G. J. et al. Mol. Ther. 3, 565-573 (2001).